Page last updated: 2024-09-04

cositecan and camptothecin

cositecan has been researched along with camptothecin in 19 studies

Compound Research Comparison

Studies
(cositecan)
Trials
(cositecan)
Recent Studies (post-2010)
(cositecan)
Studies
(camptothecin)
Trials
(camptothecin)
Recent Studies (post-2010) (camptothecin)
205213,0022,2295,391

Protein Interaction Comparison

ProteinTaxonomycositecan (IC50)camptothecin (IC50)
Histone deacetylase 3Homo sapiens (human)0.05
Multidrug resistance-associated protein 4Homo sapiens (human)7.4
DNA topoisomerase 1Homo sapiens (human)1.9799
Somatostatin receptor type 1Homo sapiens (human)0.0022
Somatostatin receptor type 2Homo sapiens (human)0.0022
Somatostatin receptor type 4Homo sapiens (human)0.0022
Somatostatin receptor type 3Homo sapiens (human)0.0022
Somatostatin receptor type 5Homo sapiens (human)0.0022
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.97
Histone deacetylase 4Homo sapiens (human)0.05
Histone deacetylase 1Homo sapiens (human)0.05
Histone deacetylase 7Homo sapiens (human)0.05
Histone deacetylase 2Homo sapiens (human)0.05
Polyamine deacetylase HDAC10Homo sapiens (human)0.05
Histone deacetylase 11 Homo sapiens (human)0.05
Histone deacetylase 8Homo sapiens (human)0.05
Histone deacetylase 6Homo sapiens (human)0.05
Histone deacetylase 9Homo sapiens (human)0.05
Histone deacetylase 5Homo sapiens (human)0.05

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (89.47)29.6817
2010's2 (10.53)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Azrak, RG; Frank, C; Guo, B; Minderman, H; Rustum, YM; Slocum, HK; Vanhoefer, U; Wrzosek, C; Yin, MB1
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH2
Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH1
Bigner, DD; Friedman, HS; Hausheer, F; Keir, ST; Lawless, AA1
Hausheer, F; Madden, TL; Newman, RA; Smith, JA1
Azrak, RG; Frank, C; Hapke, G; Rustum, YM; Wrzosek, C; Wu, J; Yin, MB1
Bailly, C; Lansiaux, A1
Hausheer, FH; Madden, T; Newman, RA; Smith, JA1
Aleksic, A; Berg, SL; Blaney, SM; Dauser, R; Hausheer, F; Kerr, JZ; McGuffey, L; Nuchtern, JG; Thompson, PA1
Berghorn, E; Centeno, B; Daud, A; Deconti, RC; Derderian, J; Hausheer, F; Liu, Z; Munster, P; Sullivan, D; Sullivan, P; Urbas, P; Valkov, N1
Green, MR; Gu, L; Herndon, JE; Miller, AA1
Berg, SL; Blaney, SM; D'Argenio, DZ; Jacob, E; Scorsone, K1
Batchelor, T; Carson, KA; Grossman, SA; Hausheer, F; Lesser, G; Nabors, LB; Peereboom, D; Phuphanich, S; Supko, JG1
Beijnen, JH; Kenworthy, KE; Oostendorp, RL; Schellens, JH; Schinkel, AH; van de Steeg, E; van der Kruijssen, CM1
Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM1
Pappo, A; Paulino, AC1
Daud, AI; Munster, PN1
Chen, X; Ding, D; Hausheer, F; Huang, Q; Kochat, H; Parker, A; Petluru, P; Yao, S1

Reviews

1 review(s) available for cositecan and camptothecin

ArticleYear
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:11

    Topics: Animals; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors

2011

Trials

4 trial(s) available for cositecan and camptothecin

ArticleYear
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8

    Topics: Adult; Aged; Anemia; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Fatigue; Female; HL-60 Cells; Humans; Male; Melanoma; Middle Aged; Nausea; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting

2005
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3

    Topics: Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome

2005
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
    Neuro-oncology, 2008, Volume: 10, Issue:4

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local

2008
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-01, Volume: 15, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histones; Humans; Male; Melanoma; Mice; Mice, Nude; Middle Aged; Skin Neoplasms; Topoisomerase I Inhibitors; Valproic Acid

2009

Other Studies

14 other study(ies) available for cositecan and camptothecin

ArticleYear
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
    Molecular pharmacology, 2000, Volume: 57, Issue:3

    Topics: Camptothecin; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Division; Checkpoint Kinase 1; Cyclin B; DNA Fragmentation; DNA Topoisomerases, Type I; Electrophoresis, Gel, Pulsed-Field; Head and Neck Neoplasms; Humans; Phosphorylation; Protein Kinases; Topoisomerase I Inhibitors; Tumor Cells, Cultured

2000
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
    International journal of cancer, 2000, Oct-15, Volume: 88, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000
New analogues of camptothecins. Activity and resistance.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous

2001
Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine.
    Journal of chromatography. B, Biomedical sciences and applications, 2001, Aug-05, Volume: 759, Issue:1

    Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence

2001
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
    International journal of cancer, 2002, Jul-01, Volume: 100, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured

2002
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
    Biochemical and biophysical research communications, 2002, Jul-12, Volume: 295, Issue:2

    Topics: 14-3-3 Proteins; Camptothecin; Cell Division; Checkpoint Kinase 1; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; G2 Phase; Humans; Mitosis; Oligonucleotides, Antisense; Phosphorylation; Protein Kinases; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase

2002
[A symphony for the camptothecins].
    Bulletin du cancer, 2003, Volume: 90, Issue:3

    Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan

2003
Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.
    Journal of clinical pharmacology, 2003, Volume: 43, Issue:9

    Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; In Vitro Techniques; Isoenzymes; Orosomucoid; Protein Binding; Serum Albumin

2003
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:6

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Catheters, Indwelling; Injections, Intravenous; Macaca mulatta; Topoisomerase I Inhibitors

2004
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Child; Cyclophosphamide; Drug Synergism; Humans; Leukemia; Medulloblastoma; Neuroblastoma

2008
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:4

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line; Dogs; Humans; Liver-Specific Organic Anion Transporter 1; Neoplasm Proteins; Organic Anion Transporters

2009
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine

2009
Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Antineoplastic Agents; Binding Sites; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydrolysis; Kinetics; Lactones; Molecular Structure; Orosomucoid; Protein Binding; Serum Albumin

2015